Phase 2 Crohn's Disease and Colitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with ulcerative colitis (UC) for at least 3 months before joining, confirmed by a camera examination of the bowel (endoscopy)
- Your UC is considered moderately to severely active, based on specific scoring systems that measure symptoms like rectal bleeding (confirm with trial site)
- Your UC affects areas of the bowel beyond just the rectum (i.e., it extends further up into the colon)
- If you have had UC symptoms for more than 8 years, you have had a bowel cancer screening (colonoscopy) within the past year, or as recommended by local guidelines
- You have tried at least one standard treatment (such as steroids) or one advanced treatment (such as a biologic medicine), but it either did not work well enough, stopped working, or caused side effects you could not tolerate
- You are able and willing to follow the contraception requirements set out by the trial
Who may not be able to join:
- You have been diagnosed with Crohn's disease, unclassified inflammatory bowel disease, or a liver condition called primary sclerosing cholangitis
- You have an inherited condition that affects your immune system, or a known genetic cause of bowel inflammation similar to UC
- You have already had surgery to remove part of your bowel, or are expected to need such surgery
- You have serious bowel complications such as toxic megacolon, an abscess inside the abdomen, or a significant narrowing of the bowel
- You have current or past evidence of cancer in the digestive tract, or certain abnormal tissue changes that could increase the risk of digestive cancer
- You have been diagnosed with any cancer in the last 5 years
- You have previously tried a medication called vedolizumab and it did not work adequately for you
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Phone: 1-317-615-4559
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of Participants Who Achieve Clinical Remission with Modified Mayo Score (mMS); Percentage of Participants Who Achieve Clinical Remission with mMS Among Participants Who Achieved Clinical Response with LY4268989 at Week 10
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.